Comparison · NCT01920711-492cca16
LCZ696 vs Valsartan: All-cause Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. LCZ696 vs Valsartan: All-cause Mortality. Trial comparisons, record NCT01920711-492cca16. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01920711-492cca16
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.142 | 0.129 | 0.157 | wilson | |
| Risk in group 2 | 0.146 | 0.132 | 0.161 | wilson | |
| Risk difference, group 1 minus group 2 | -0.004 | -0.0239 | 0.0159 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.973 | 0.847 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 0.968 | 0.824 | 1.14 | log | |
| Number needed to treat, for one fewer participant with the outcome on LCZ696 than on Valsartan | 250 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | LCZ696 | Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients followed by Valsartan 80 mg bid for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of LCZ696 during the double blind period was 200 mg bid | 342 | 2,407 | OG000 |
| Group 2 | Valsartan | Single Blind Run-in Period (3-8 weeks): Prior optional valsartan run-in 40 mg bid for 1-2 weeks for some patients, followed by Valsartan 80 mg bid. for 1-2 weeks followed by LCZ696 100 mg bid for 2-4 weeks prior to randomization into the Double Blind period (up to 57 months). Patients could only be randomized from the run-in period if they met all of the run-in safety criteria. Target dose of Valsartan during the double blind period was 160 mg bid | 349 | 2,389 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- All-cause Mortality
- Description
- Analysis for all-cause mortality using Cox's proportional hazards model.
- Time frame
- Randomization to total follow up time (up to 57 months)
- Population
- Full Analysis Set -This was the primary efficacy population applied in efficacy analyses for all efficacy endpoints.
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction
- NCT number
- NCT01920711
- Phases
- PHASE3
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- LCZ696, Valsartan
- Lead sponsor
- Novartis Pharmaceuticals
- Results first posted
- 2020-09-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01920711?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01920711-492cca16